Nicox SA (FR:ALCOX) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nicox SA, a French ophthalmology company, reported a second-quarter 2024 revenue of €1.6 million and a cash position of €7.8 million, which finances the company till February 2025. Progress was marked by a successful equity raise of €3.3 million and nearing completion of the Denali Phase 3 trial for its lead drug candidate, NCX 470. The company is also considering strategic options and pursuing business development discussions to extend its cash runway.
For further insights into FR:ALCOX stock, check out TipRanks’ Stock Analysis page.